Fosun Pharma, TPG make China healthcare move

Take-private bid for Chindex offers US private equity group exposure to China's burgeoning healthcare sector.

Shanghai Fosun Pharmaceutical Fosun Pharma and US private equity firm TPG have made an offer to take Nasdaq-listed healthcare company Chindex private in a $369 million deal.

The move offers TPG the chance to gain exposure to China's growing healthcare sector, an area that the government has been loosening restrictions on.

It also will enable the Chinese group’s management to partner two deep-pocketed players in its expansion drive.

Fosun Pharma already holds a 17.4% stake in Chindex and, after the deal, this will rise to 48.6%. TPG's stake will be 48.1% and the management's stake, including that of chief executive Roberta Lipson, will...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222